The results of the study indicate significantly higher bone-strength parameters compared to a standard vegetable oil control.
Yael Lifshitz, director of R&D, Enzymotec Infant Nutrition, said: “We are very pleased with the study results. This clearly indicates that InFat benefits bone strength parameters. Bone speed of sound of the newborns fed the formula with InFat was significantly higher than that of newborns fed the control formula, and comparable to that of breast-fed newborns.”
Tzafra Cohen, CEO of Advanced Lipids, said: “This trial marks an important milestone in our clinical development programme, positioning InFat as a premium fat blend for infant formulas.
“It shows Advanced Lipids’ commitment to our customers and the infant nutrition market to continued investment in research. We also anticipate finding additional benefits to the use of InFat.”
InFat is a clinically proven fat blend (beta-palmitate structured lipids) for infant formula with a high percentage of palmitic acid in its sn-2 position. This mimics the unique composition of human milk fat, which is highly conserved in all women’s breast milk, and thereby enables optimised uptake of calcium and energy as well as easy digestion.
Source: Enzymotec
© FoodBev Media Ltd 2024